MedTrace Logo

Targeted Naltrexone for Problem Drinkers

NCT00369408 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2011-06-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether naltrexone, combined with brief coping skills therapy, is effective in the treatment of heavy drinking.

Conditions

  • Alcoholism
  • Alcohol Drinking
  • Alcohol Dependence

Interventions

DRUG

Naltrexone

naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up

DRUG

placebo

placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • UConn Health

    lead OTHER

Principal Investigators

  • Henry R. Kranzler, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2007-08-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00369408 on ClinicalTrials.gov